Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Philip J Saylor, M.D.

Title
Institution
Department
Address

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Shankar GM, Van Beaver LA, Choi BD, Hadzipasic M, Sivaganesan A, Karhade AV, Ferrone ML, Harris MB, Schoenfeld AJ, Sadow PM, Oh K, Schwab JH, Saylor PJ, Shin JH. Survival After Surgery for Renal Cell Carcinoma Metastatic to the Spine: Impact of Modern Systemic Therapies on Outcomes. Neurosurgery. 2020 Jun 10. PMID: 32521012.
    Citations:    
  2. Massaad E, Hadzipasic M, Alvarez-Breckenridge C, Kiapour A, Fatima N, Schwab JH, Saylor P, Oh K, Schoenfeld AJ, Shankar GM, Shin JH. Predicting tumor-specific survival in patients with spinal metastatic renal cell carcinoma: which scoring system is most accurate? J Neurosurg Spine. 2020 Jun 05; 1-11. PMID: 32502990.
    Citations:    
  3. Saylor PJ, Rumble RB, Michalski JM. Bone Health and Bone-Targeted Therapies for Prostate Cancer: American Society of Clinical Oncology Endorsement Summary of a Cancer Care Ontario Guideline. JCO Oncol Pract. 2020 Feb 19; JOP1900778. PMID: 32074010.
    Citations:    
  4. Saylor PJ, Rumble RB, Tagawa S, Eastham JA, Finelli A, Reddy PS, Kungel TM, Nissenberg MG, Michalski JM. Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. J Clin Oncol. 2020 May 20; 38(15):1736-1743. PMID: 31990618.
    Citations:    
  5. Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 12; 17(12):1529-1554. PMID: 31805523.
    Citations:    
  6. Karhade AV, Thio QCBS, Ogink PT, Bono CM, Ferrone ML, Oh KS, Saylor PJ, Schoenfeld AJ, Shin JH, Harris MB, Schwab JH. Predicting 90-Day and 1-Year Mortality in Spinal Metastatic Disease: Development and Internal Validation. Neurosurgery. 2019 10 01; 85(4):E671-E681. PMID: 30869143.
    Citations:    
  7. Amorim BJ, Prabhu V, Marco SS, Gervais D, Palmer WE, Heidari P, Vangel M, Saylor PJ, Catalano OA. Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2020 Jan; 47(1):105-114. PMID: 31492992.
    Citations:    
  8. Karhade AV, Thio QCBS, Ogink PT, Shah AA, Bono CM, Oh KS, Saylor PJ, Schoenfeld AJ, Shin JH, Harris MB, Schwab JH. Development of Machine Learning Algorithms for Prediction of 30-Day Mortality After Surgery for Spinal Metastasis. Neurosurgery. 2019 07 01; 85(1):E83-E91. PMID: 30476188.
    Citations:    Fields:    
  9. Saylor PJ, Dudzinski DM, Mendoza DP, Glomski K. Case 14-2019: A 44-Year-Old Man with Neck Pain and Swelling. N Engl J Med. 2019 May 09; 380(19):1854-1863. PMID: 31067377.
    Citations:    
  10. Dahl DM, Simeone JF, Iliopoulos O, Saylor PJ, Wu CL. Case 36-2018: A 29-Year-Old Man with an Incidentally Discovered Renal Mass. N Engl J Med. 2018 11 22; 379(21):2064-2072. PMID: 30462933.
    Citations:    Fields:    Translation:Humans
  11. Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani AB, Kucuk O, Souhami L, Rodgers JP, Sandler HM, Shipley WU. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol. 2019 01 01; 37(1):44-51. PMID: 30433852.
    Citations:    Fields:    
  12. Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017 06; 71(6):952-960. PMID: 28081860.
    Citations: 7     Fields:    Translation:Humans
  13. Saylor PJ, Lee RJ, Arora KS, Deshpande V, Hu R, Olivier K, Meneely E, Rivera MN, Ting DT, Wu CL, Miyamoto DT. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. Clin Cancer Res. 2017 Jan 15; 23(2):363-369. PMID: 27440270.
    Citations: 3     Fields:    Translation:HumansCells
  14. Singh H, Liu Y, Xiao X, Lin L, Kim J, Van Hummelen P, Wu CL, Bass AJ, Saylor PJ. Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations. Oncotarget. 2016 May 17; 7(20):29211-5. PMID: 27078850.
    Citations: 3     Fields:    Translation:Humans
  15. Pallais JC, McInnis M, Saylor PJ, Wu RI. CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 38-2015. A 21-Year-Old Man with Fatigue and Weight Loss. N Engl J Med. 2015 Dec 10; 373(24):2358-69. PMID: 26650156.
    Citations:    Fields:    Translation:Humans
  16. Ryan CJ, Saylor PJ, Everly JJ, Sartor O. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data. Oncologist. 2014 Oct; 19(10):1012-8. PMID: 25232039.
    Citations: 6     Fields:    Translation:Humans
  17. Saylor PJ. Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer. Asian J Androl. 2014 May-Jun; 16(3):341-7. PMID: 24435057.
    Citations: 4     Fields:    Translation:HumansCells
  18. Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014 Apr 10; 32(11):1143-50. PMID: 24590644.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  19. Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013 Jun 01; 19(11):3088-94. PMID: 23553848.
    Citations: 33     Fields:    Translation:HumansCells
  20. Saylor PJ, Smith MR, O'Malley AJ, Keating NL. Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer. Eur Urol. 2014 Mar; 65(3):642-9. PMID: 23428068.
    Citations:    Fields:    Translation:Humans
  21. Saylor PJ. Prostate cancer: The androgen receptor remains front and centre. Nat Rev Clin Oncol. 2013 03; 10(3):126-8. PMID: 23381000.
    Citations: 13     Fields:    Translation:Humans
  22. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4. PMID: 23234628.
    Citations: 30     Fields:    Translation:Humans
  23. Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol. 2013 Feb; 63(2):309-20. PMID: 23201471.
    Citations: 11     Fields:    Translation:Humans
  24. Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer. J Nucl Med. 2012 Nov; 53(11):1670-5. PMID: 22984218.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  25. Saylor PJ, Karoly ED, Smith MR. Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer. Clin Cancer Res. 2012 Jul 01; 18(13):3677-85. PMID: 22589396.
    Citations: 17     Fields:    Translation:HumansCells
  26. Saylor PJ, Escudier B, Michaelson MD. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy. Clin Genitourin Cancer. 2012 Jun; 10(2):77-83. PMID: 22382009.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  27. Psutka SP, Olumi AF, Feldman AS, Saylor PJ, Kaufman DS, Lee RJ. Pathologic down-staging and complete pathologic response with gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder. J Clin Oncol. 2012 Feb 10; 30(5_suppl):307. PMID: 28143141.
    Citations:    
  28. Saylor PJ, Karoly ED, Smith MR. Changes in plasma metabolomic profiles during the first 3 months of androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):116. PMID: 28143032.
    Citations:    
  29. Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist. 2012; 17(2):212-9. PMID: 22302227.
    Citations: 13     Fields:    Translation:Humans
  30. Saylor PJ, Michaelson MD. Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer? Oncologist. 2012; 17(2):288-90. PMID: 22267850.
    Citations: 1     Fields:    Translation:Humans
  31. Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol. 2011 Sep 20; 29(27):3705-14. PMID: 21860001.
    Citations: 30     Fields:    Translation:Humans
  32. Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS, Smith MR. Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2011 Aug; 186(2):482-6. PMID: 21679977.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  33. Tabatabaei S, Saylor PJ, Coen J, Dahl DM. Prostate cancer imaging: what surgeons, radiation oncologists, and medical oncologists want to know. AJR Am J Roentgenol. 2011 Jun; 196(6):1263-6. PMID: 21606287.
    Citations: 3     Fields:    Translation:Humans
  34. Saylor PJ. Targeted therapies: denosumab--a new option for solid tumors metastatic to bone. Nat Rev Clin Oncol. 2011 Jun; 8(6):322-4. PMID: 21556026.
    Citations: 2     Fields:    Translation:Humans
  35. Saylor PJ, Keating NL, Freedland SJ, Smith MR. Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. Drugs. 2011 Feb 12; 71(3):255-61. PMID: 21319864.
    Citations: 1     Fields:    Translation:Humans
  36. Lee RJ, Saylor PJ, Smith MR. Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer. 2010 Dec 01; 8(1):29-36. PMID: 21208853.
    Citations: 11     Fields:    Translation:HumansCells
  37. Saylor PJ. Re: Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy. Editorial comment. J Urol. 2010 Sep; 184(3):923; author reply 924. PMID: 20643451.
    Citations:    Fields:    
  38. Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol. 2010 Jun; 183(6):2200-5. PMID: 20399451.
    Citations: 15     Fields:    Translation:Humans
  39. Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone. 2011 Jan; 48(1):88-95. PMID: 20621630.
    Citations: 28     Fields:    Translation:HumansCells
  40. Saylor PJ, Fogerty AE. Prostate-cancer-associated hypercoagulability: do we need to worry about androgen deprivation? Lancet Oncol. 2010 May; 11(5):406-7. PMID: 20395175.
    Citations:    Fields:    Translation:Humans
  41. Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw. 2010 Feb; 8(2):211-23. PMID: 20141678.
    Citations: 16     Fields:    Translation:Humans
  42. Saylor PJ, Smith MR. Bone health and prostate cancer. Prostate Cancer Prostatic Dis. 2010 Mar; 13(1):20-7. PMID: 19901958.
    Citations: 10     Fields:    Translation:HumansCells
  43. Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med. 2009 Nov; 24 Suppl 2:S389-94. PMID: 19838837.
    Citations: 15     Fields:    Translation:Humans
  44. Saylor PJ, Smith MR. Prostate cancer: How can we improve the health of men who receive ADT? Nat Rev Urol. 2009 Oct; 6(10):529-31. PMID: 19806171.
    Citations: 2     Fields:    Translation:Humans
  45. Saylor PJ, Michaelson MD. New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Canc Netw. 2009 Jun; 7(6):645-56. PMID: 19555586.
    Citations: 8     Fields:    Translation:Humans
  46. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009 May; 181(5):1998-2006; discussion 2007-8. PMID: 19286225.
    Citations: 56     Fields:    Translation:Humans
  47. Saylor PJ, Reid TR. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol. 2007 Aug 10; 25(23):3544-6. PMID: 17687160.
    Citations: 3     Fields:    Translation:Humans
  48. Saylor P, Hanna E, Adams JA. Mutations in the activation loop tyrosine of the oncoprotein v-Fps. Biochemistry. 1998 Dec 22; 37(51):17875-81. PMID: 9922154.
    Citations: 1     Fields:    Translation:AnimalsCells
  49. Saylor P, Wang C, Hirai TJ, Adams JA. A second magnesium ion is critical for ATP binding in the kinase domain of the oncoprotein v-Fps. Biochemistry. 1998 Sep 08; 37(36):12624-30. PMID: 9730835.
    Citations: 8     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Saylor's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (206)
Explore
_
Co-Authors (49)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.